• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Executive Officer Lai Gang was granted 71,890 units of Class A ordinary shares and was granted 12,610 units of Class B ordinary shares (SEC Form 4)

    5/21/26 4:16:12 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $UPC alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Lai Gang

    (Last)(First)(Middle)
    265 JINGJIU AVENUE
    JINGGANGSHAN ECON. AND TECH. DEV. ZONE

    (Street)
    JI'AN, JIANGXIJIANGXI343100

    (City)(State)(Zip)

    CHINA

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    Universe Pharmaceuticals INC [ UPC ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirectorX10% Owner
    XOfficer (give title below)Other (specify below)
    Chief Executive Officer
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    05/07/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Class A ordinary shares, par value US$0.00001 per share05/07/2026A71,890A(1)71,890D
    Class B ordinary shares, par value US$0.00001 per share05/07/2026A12,610A(1)12,610D
    Class B ordinary shares, par value US$0.00001 per share3,467IBy Sununion Holding Group Limited(2)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Explanation of Responses:
    1. Represents a grant of ordinary shares under the Issuer's 2026 Equity Incentive Plan, in a transaction exempt under Rule 16b-3, in consideration for past services rendered by the Reporting Person. The grant is subject to the terms of an award agreement entered into by and between the Reporting Person and the Issuer, dated May 5, 2026.
    2. Represents 3,467 Class B ordinary shares held by Sununion Holding Group Limited, a business company incorporated in the British Virgin Islands, which is owned as to 100% and controlled by Gang Lai. The registered address of Sununion Holding Group Limited is Vistra Corporate Services Centre, Wickhams Cay II, Road Town, Tortola, VG1110, British Virgin Islands.
    /s/ Gang Lai05/21/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $UPC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $UPC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $UPC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    4 Sizzling Biotech and Healthcare Companies Reporting Strategic Milestones

    DENVER, June 29, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – As the second half of 2026 begins, a series of regulatory approvals, strategic acquisitions, clinical development milestones, and financing initiatives are highlighting continued activity across the biotechnology and healthcare sectors, as companies work to expand pipelines, strengthen balance sheets, and advance toward commercialization. Universe Pharmaceuticals (NASDAQ:UPC) announced a definitive agreement to acquire Best Praise International Limited, a transaction that would add five China-based pharmaceutical patents to the company's intellectual property portfolio. The all-stock acquisition, valued at approximately $10.7

    6/29/26 9:50:32 AM ET
    $UPC
    $DCOY
    $VRDN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    Universe Pharmaceuticals INC Announces Strategic Acquisition to Expand Pharmaceutical Patent Portfolio

    Ji'an, Jiangxi, China, June 26, 2026 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ:UPC) ("Universe Pharmaceuticals" or the "Company"), a pharmaceutical producer and distributor in China, today announced that the Company has entered into a share purchase agreement to acquire 100% of the issued shares of Best Praise International Limited ("Best Praise"), a company that holds five patents in China with potential applications in pharmaceutical development, for a total purchase price of US$10,751,000, payable in the form of 4,376,552 Class A ordinary shares of the Company. The patent portfolio covers several pharmaceutical and healthcare-related areas, including age-related disease

    6/26/26 4:05:00 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Universe Pharmaceuticals INC Announces Effective Date of Dual-Class Share Structure

    Ji'an, Jiangxi, China, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ:UPC) ("Universe Pharmaceuticals" or the "Company"), a pharmaceutical producer and distributor in China, today announced that all conditions to the implementation of its dual-class share structure have been satisfied and that its dual-class share structure will become effective on the Nasdaq Capital Market on February 13, 2026. In connection with the implementation of its dual-class share structure, the Company amended and restated its memorandum and articles of association and the Company's authorized share capital was changed to US$20,000 divided into 1,800,000,000 class A ordinary shares of pa

    2/11/26 4:05:00 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UPC
    SEC Filings

    View All

    SEC Form 6-K filed by Universe Pharmaceuticals Inc.

    6-K - Universe Pharmaceuticals INC (0001809616) (Filer)

    6/26/26 4:06:21 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Universe Pharmaceuticals Inc.

    6-K - Universe Pharmaceuticals INC (0001809616) (Filer)

    5/14/26 4:10:16 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Universe Pharmaceuticals Inc.

    6-K - Universe Pharmaceuticals INC (0001809616) (Filer)

    4/16/26 4:10:15 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UPC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Lai Gang was granted 71,890 units of Class A ordinary shares and was granted 12,610 units of Class B ordinary shares (SEC Form 4)

    4 - Universe Pharmaceuticals INC (0001809616) (Issuer)

    5/21/26 4:16:12 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by Universe Pharmaceuticals Inc.

    3 - Universe Pharmaceuticals INC (0001809616) (Issuer)

    3/18/26 8:27:11 AM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by Universe Pharmaceuticals Inc.

    3 - Universe Pharmaceuticals INC (0001809616) (Issuer)

    3/18/26 8:25:06 AM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UPC
    Leadership Updates

    Live Leadership Updates

    View All

    Universe Pharmaceuticals INC Appoints Mr. Baochang Liu as Chief Operating Officer

    Ji'an, Jiangxi, China, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the "Company") (NASDAQ:UPC), a pharmaceutical producer and distributor in China, today announced that the Company appointed Mr. Baochang Liu as its Chief Operating Officer, effective December 1, 2021. Mr. Baochang Liu has over 17 years of experience in pharmaceutical marketing. Mr. Baochang Liu has been working as the vice president of marketing and general manager of OTC department at China Shineway Pharmaceutical Group Ltd. since December 2019. Mr. Baochang Liu served as the general manager of OTC department at Chengdu Kanghong Pharmaceutical Group Co., Ltd. from November 2015 to December 2019. Prior

    12/15/21 4:30:00 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UPC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Universe Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Universe Pharmaceuticals INC (0001809616) (Subject)

    2/14/23 2:14:41 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Universe Pharmaceuticals Inc.

    SC 13G - Universe Pharmaceuticals INC (0001809616) (Subject)

    2/11/22 8:00:43 AM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Universe Pharmaceuticals Inc.

    SC 13G - Universe Pharmaceuticals INC (0001809616) (Subject)

    12/28/21 4:10:53 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care